{"id":"sch-58235","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Peripheral edema"}]},"_chembl":{"chemblId":"CHEMBL513136","moleculeType":"Small molecule","molecularWeight":"397.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Endothelin-1 is a potent vasoconstrictor that plays a key role in the pathophysiology of pulmonary hypertension. By selectively antagonizing endothelin receptors, SCH-58235 promotes vasodilation and reduces the proliferation of pulmonary vascular smooth muscle cells. This mechanism helps restore normal pulmonary hemodynamics and improve exercise capacity in patients with pulmonary hypertension.","oneSentence":"SCH-58235 is a selective endothelin receptor antagonist that blocks endothelin-1 signaling to reduce pulmonary vascular resistance and improve hemodynamics in pulmonary hypertension.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:33:38.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension"}]},"trialDetails":[{"nctId":"NCT04862260","phase":"EARLY_PHASE1","title":"Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2021-10-04","conditions":"Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer","enrollment":3},{"nctId":"NCT07268625","phase":"PHASE1","title":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-12-09","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT07235189","phase":"PHASE1","title":"A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-10-28","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT05641753","phase":"PHASE4","title":"Cholesterol Lowering and Residual Risk in Diabetes, Type 1","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-12-06","conditions":"Type 1 Diabetes","enrollment":125},{"nctId":"NCT07201545","phase":"PHASE1","title":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-10-07","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT04508907","phase":"PHASE4","title":"A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-09-10","conditions":"Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection","enrollment":200},{"nctId":"NCT07182383","phase":"PHASE1","title":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-09-29","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT05910476","phase":"PHASE4","title":"Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2023-05-03","conditions":"Coronary Artery Disease, Dyslipidemias","enrollment":200},{"nctId":"NCT06314919","phase":"","title":"A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2024-03-15","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":8606},{"nctId":"NCT04638400","phase":"PHASE4","title":"Anti-inflammatory Effects of Simvastatin","status":"TERMINATED","sponsor":"paresh Dandona","startDate":"2017-05-01","conditions":"Inflammation, Atherosclerosis, Hypercholesterolemia","enrollment":10},{"nctId":"NCT04369664","phase":"PHASE4","title":"CHOlesterol Lowering and Residual Risk in Type 2 Diabetes","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-12","conditions":"Type 2 Diabetes","enrollment":151},{"nctId":"NCT01414192","phase":"","title":"A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11-15","conditions":"Dyslipidemia, Hypercholesterolemia","enrollment":3215},{"nctId":"NCT00651963","phase":"PHASE4","title":"Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-09","conditions":"Lipid Metabolism Disorder","enrollment":80},{"nctId":"NCT00653276","phase":"PHASE1","title":"MD Ezetimibe Cyclosporine Interaction (0653-057)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-11","conditions":"Cholesterol","enrollment":13},{"nctId":"NCT00652847","phase":"PHASE4","title":"Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Hypercholesterolemia","enrollment":1140},{"nctId":"NCT00652717","phase":"PHASE4","title":"Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-01","conditions":"Cardiovascular Disorder","enrollment":280},{"nctId":"NCT00551876","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-12","conditions":"Diabetes Mellitus, Type 2","enrollment":214},{"nctId":"NCT00551447","phase":"PHASE3","title":"A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-01","conditions":"Coronary Disease","enrollment":616},{"nctId":"NCT00650819","phase":"PHASE3","title":"Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-06-01","conditions":"Hypercholesterolemia","enrollment":240},{"nctId":"NCT00552097","phase":"PHASE3","title":"Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-06-01","conditions":"Atherosclerosis, Hypercholesterolemia, Hyperlipoproteinemia Type II","enrollment":720},{"nctId":"NCT00650663","phase":"PHASE4","title":"Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-10-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":247},{"nctId":"NCT00653796","phase":"PHASE4","title":"Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":148},{"nctId":"NCT00653835","phase":"PHASE4","title":"Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-01","conditions":"Hypercholesterolaemia, Atherosclerosis","enrollment":153},{"nctId":"NCT00651378","phase":"PHASE4","title":"Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2004-09-01","conditions":"Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease","enrollment":87},{"nctId":"NCT00651274","phase":"PHASE4","title":"Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-04-01","conditions":"Atherosclerosis, Hypercholesterolemia, Coronary Heart Disease","enrollment":144},{"nctId":"NCT00651391","phase":"PHASE3","title":"Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2003-10-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":28},{"nctId":"NCT01611883","phase":"PHASE4","title":"A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-07-02","conditions":"Hypercholesterolemia","enrollment":152},{"nctId":"NCT00653523","phase":"PHASE3","title":"Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-12-01","conditions":"Hypercholesterolemia","enrollment":151},{"nctId":"NCT00867165","phase":"PHASE3","title":"Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-05-21","conditions":"Primary Hypercholesterolemia","enrollment":138},{"nctId":"NCT00654095","phase":"PHASE3","title":"Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-12-01","conditions":"Hypercholesterolemia","enrollment":146},{"nctId":"NCT00783263","phase":"PHASE3","title":"A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11","conditions":"Hypercholesterolemia","enrollment":440},{"nctId":"NCT03867110","phase":"PHASE3","title":"An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-03-06","conditions":"Hypercholesterolemia","enrollment":628},{"nctId":"NCT03882905","phase":"PHASE3","title":"A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-01-31","conditions":"Primary Hypercholesterolemia","enrollment":769},{"nctId":"NCT03882892","phase":"PHASE3","title":"Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-02-02","conditions":"Hypercholesterolemia","enrollment":400},{"nctId":"NCT03884452","phase":"PHASE3","title":"Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-05-03","conditions":"Familial Hypercholesterolemia","enrollment":50},{"nctId":"NCT03867318","phase":"PHASE3","title":"Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04-24","conditions":"Hypercholesterolemia","enrollment":621},{"nctId":"NCT05543122","phase":"","title":"Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2022-03-09","conditions":"Breast Feeding","enrollment":39},{"nctId":"NCT00988364","phase":"PHASE4","title":"Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2007-03","conditions":"Metabolic Syndrome","enrollment":30},{"nctId":"NCT05970679","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2022-08-17","conditions":"Hypercholesterolemia, Dyslipidemia","enrollment":252},{"nctId":"NCT05681247","phase":"PHASE1","title":"Bioavailability and Bioequivalence of Ezetimibe Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2017-12-17","conditions":"Hyperlipidemias","enrollment":59},{"nctId":"NCT01375777","phase":"PHASE2","title":"Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07-06","conditions":"Hyperlipidemia","enrollment":411},{"nctId":"NCT01763866","phase":"PHASE3","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-15","conditions":"Hyperlipidemia","enrollment":2067},{"nctId":"NCT01763827","phase":"PHASE3","title":"Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-21","conditions":"Hyperlipidemia","enrollment":615},{"nctId":"NCT01375764","phase":"PHASE2","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07-28","conditions":"Hyperlipidemia","enrollment":160},{"nctId":"NCT05481385","phase":"PHASE1","title":"Bioequivalence Study of Ezetimibe Tablets Under Fed Conditions in Healthy Subjects","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2022-07-15","conditions":"Pharmacokinetics, Safety","enrollment":48},{"nctId":"NCT02971033","phase":"PHASE2","title":"Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2018-04-16","conditions":"Chronic Hepatitis C","enrollment":2},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT00652444","phase":"PHASE4","title":"Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09","conditions":"Hypercholesterolemia","enrollment":120},{"nctId":"NCT00651404","phase":"PHASE3","title":"Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":137},{"nctId":"NCT03885921","phase":"PHASE3","title":"Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-10-25","conditions":"Hypercholesterolemia","enrollment":44},{"nctId":"NCT00650689","phase":"PHASE3","title":"Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":"Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease","enrollment":122},{"nctId":"NCT03882996","phase":"PHASE3","title":"A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-10-06","conditions":"Hypercholesterolemia","enrollment":432},{"nctId":"NCT00651144","phase":"PHASE1","title":"Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":40},{"nctId":"NCT00651014","phase":"PHASE4","title":"Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2004-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":82},{"nctId":"NCT00653913","phase":"PHASE1","title":"Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT00705211","phase":"","title":"A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-06","conditions":"Hypercholesterolemia, Familial Hypercholesterolemia, Homozygous Sitosterolemia","enrollment":1794},{"nctId":"NCT00202904","phase":"PHASE4","title":"Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Hypercholesterolemia, Coronary Heart Disease","enrollment":81},{"nctId":"NCT00704444","phase":"","title":"A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-06","conditions":"Hypercholesterolemia, Familial Hypercholesterolemia, Homozygous Sitosterolemia","enrollment":11332},{"nctId":"NCT00726856","phase":"","title":"Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05","conditions":"Dyslipidemia","enrollment":1200},{"nctId":"NCT01236430","phase":"PHASE1","title":"A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-02","conditions":"Hyperlipidemia","enrollment":200},{"nctId":"NCT00704535","phase":"","title":"Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-03","conditions":"Primary Hypercholesterolemia, Homozygous Familial Hypercholesterolemia","enrollment":4105},{"nctId":"NCT00705081","phase":"","title":"Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-01","conditions":"Hypercholesterolemia","enrollment":453},{"nctId":"NCT00730132","phase":"","title":"Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-01","conditions":"Coronary Heart Disease, Hypercholesterolemia","enrollment":712},{"nctId":"NCT01370603","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09","conditions":"Hypercholesterolemia","enrollment":328},{"nctId":"NCT01370590","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09","conditions":"Hypercholesterolemia","enrollment":406},{"nctId":"NCT01070953","phase":"","title":"EZETROL® Re-examination Study (MK0653-175)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01","conditions":"Hypercholesterolemia","enrollment":4467},{"nctId":"NCT04584736","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2019-06-11","conditions":"Primary Hypercholesterolemia","enrollment":283},{"nctId":"NCT05081336","phase":"","title":"Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry","status":"UNKNOWN","sponsor":"University Clinical Centre of Republic of Srpska","startDate":"2021-03-01","conditions":"Acute Coronary Syndrome, Dyslipidemias","enrollment":500},{"nctId":"NCT04895059","phase":"PHASE1","title":"Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual Components","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2017-04-30","conditions":"Healthy","enrollment":36},{"nctId":"NCT03355027","phase":"NA","title":"Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-11-30","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT04844996","phase":"EARLY_PHASE1","title":"Antilipidemic Ezetimibe Induces Regression of Endometriotic Explants in a Rat Model of Endometriosis","status":"COMPLETED","sponsor":"Mersin University","startDate":"2019-09-01","conditions":"Endometriosis","enrollment":18},{"nctId":"NCT03877783","phase":"NA","title":"DEMAND - Multifactorial Study to Reduce Dementia in People With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Umeå University","startDate":"2020-10-19","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":10},{"nctId":"NCT04814589","phase":"PHASE1","title":"Bioequivalence of Ezetimibe Tablets in Healthy Subjects","status":"UNKNOWN","sponsor":"Cao Yu","startDate":"2021-03-13","conditions":"Therapeutic Equivalency","enrollment":96},{"nctId":"NCT00794677","phase":"PHASE4","title":"Effects of Ezetimibe on the Absorption of Oxidized Cholesterol","status":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2006-06","conditions":"Hypercholesterolemia","enrollment":26},{"nctId":"NCT01035320","phase":"PHASE4","title":"Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2006-01","conditions":"Diabetes Mellitus, Impaired Renal Function","enrollment":39},{"nctId":"NCT04737408","phase":"PHASE3","title":"Influence of Intensive Lipid-lowering on FFRCT (The FLOW-PROMOTE Study)","status":"UNKNOWN","sponsor":"Bjarne Linde Noergaard","startDate":"2020-05-13","conditions":"Coronary Artery Disease","enrollment":120},{"nctId":"NCT02634580","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-02-27","conditions":"Hypercholesterolemia","enrollment":61},{"nctId":"NCT00477204","phase":"PHASE2","title":"Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-05","conditions":"Type 1 Diabetes Mellitus, Dyslipidemia","enrollment":9},{"nctId":"NCT00879710","phase":"NA","title":"Effect of Diabetes Mellitus on Cholesterol Metabolism","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2008-08","conditions":"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypercholesterolemia","enrollment":57},{"nctId":"NCT01763905","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-24","conditions":"Hyperlipidemia","enrollment":307},{"nctId":"NCT01766713","phase":"PHASE2","title":"Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2013-01","conditions":"Non Alcoholic Steatohepatitis","enrollment":50},{"nctId":"NCT01709513","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-09-30","conditions":"Hypercholesterolemia","enrollment":314},{"nctId":"NCT03001076","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2016-11-29","conditions":"Hypercholesterolemia, Atherosclerosis, Statin Adverse Reaction","enrollment":269},{"nctId":"NCT03531905","phase":"PHASE2","title":"Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2018-05-09","conditions":"Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia","enrollment":242},{"nctId":"NCT03337308","phase":"PHASE3","title":"A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2017-10-23","conditions":"Hyperlipidemias","enrollment":382},{"nctId":"NCT01730053","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-11-30","conditions":"Hypercholesterolemia","enrollment":305},{"nctId":"NCT03051100","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2017-01-19","conditions":"Hypercholesterolemia","enrollment":63},{"nctId":"NCT00687076","phase":"PHASE4","title":"Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2004-04","conditions":"Peripheral Arterial Disease","enrollment":102},{"nctId":"NCT02682680","phase":"PHASE4","title":"Randomized Trial Comparing Colesevelam vs. Ezetimibe","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2016-01-11","conditions":"Type 2 Diabetes Mellitus","enrollment":200},{"nctId":"NCT00965055","phase":"PHASE3","title":"Ezetimibe in Patients Hypo-responsive to Statins","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2009-09","conditions":"High Cholesterol, Coronary Artery Disease","enrollment":2},{"nctId":"NCT01218204","phase":"PHASE2","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-14","conditions":"Dyslipidaemias, Dyslipidemias","enrollment":287},{"nctId":"NCT01941836","phase":"PHASE2","title":"Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2013-09","conditions":"Hypercholesterolemia","enrollment":349},{"nctId":"NCT01984424","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-12-10","conditions":"Hyperlipidemia","enrollment":511},{"nctId":"NCT02244944","phase":"PHASE2","title":"Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD","status":"TERMINATED","sponsor":"Gregory Graf, PhD","startDate":"2014-09","conditions":"Nonalcoholic Fatty Liver Disease (NAFLD)","enrollment":2},{"nctId":"NCT00587678","phase":"NA","title":"Comprehensive Magnetic Resonance of Peripheral Arterial Disease","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2006-01","conditions":"Peripheral Artery Disease","enrollment":85},{"nctId":"NCT01597700","phase":"PHASE1","title":"Acotral® Versus Zetia® Ezetimibe Bioequivalance Study.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-13","conditions":"Hypercholesterolaemia","enrollment":52},{"nctId":"NCT01603758","phase":"PHASE1","title":"Physiological Study of Human Cholesterol Metabolism and Excretion","status":"COMPLETED","sponsor":"Richard E. Ostlund Jr., MD","startDate":"2014-01","conditions":"Coronary Heart Disease, Cardiovascular Disease, Dyslipidemia","enrollment":132},{"nctId":"NCT01849068","phase":"PHASE3","title":"Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study","status":"COMPLETED","sponsor":"Laval University","startDate":"2013-06","conditions":"Metabolic Syndrome X","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SCH-58235","genericName":"SCH-58235","companyName":"National Heart, Lung, and Blood Institute (NHLBI)","companyId":"national-heart-lung-and-blood-institute-nhlbi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SCH-58235 is a selective endothelin receptor antagonist that blocks endothelin-1 signaling to reduce pulmonary vascular resistance and improve hemodynamics in pulmonary hypertension. Used for Pulmonary arterial hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}